Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05983991

Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation

This trial is a translational, open-label, multi-site, retrospective and prospective cohort study of 250 patients aiming to characterize predictive parameters of clonal evolution in a population of subjects carrying the germline GATA2 mutation.

This study will be conducted on a population of subjects either with previous germline GATA2 mutation identified or newly identified for germline GATA2 mutation in the context of routine care.

Prospective cohort:

150 subjects will be included in this interventional prospective cohort study:

* Alive subjects previously identified with a germline GATA2 mutation through the already existing "Neutropenia database"; * Subject identified in the investigating centers in the context of a newly identified germline GATA2 mutation.

For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.

Retrospective cohort:

Subjects (100 cases in total) previously identified with germline GATA2 mutation through the already existing "Neutropenia database" and with the following features may enter the retrospective cohort:

* Deceased patients, * Lost to follow-up patients. Clinical follow-up data will be obtained from this database and/or patient's medical report.

For each retrospective case, archived blood and bone marrow samples (collected in a sanitary setting) will be sent to sponsor's centralized unit for analysis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

GATA2 Gene Mutation Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndromes Neoplasms Neoplasms by Histologic Type

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Angers, Angers, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All subject, at any age, with a germline GATA2 mutation.
  • Patient followed in the center within a standard of care procedure or clinical trial.
  • Signed written informed consent. For minor patients: patient assent and legal guardian(s) written informed consent obtained before inclusion in the study and prior performance of any study-related procedure.
  • For French patients: patient affiliated to a Social Health Insurance.

Exclusion criteria

  • GATA2 somatic mutation.
  • Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
  • Person who has forfeited his/her freedom by administrative or legal award or who is under legal protection, with the exception of persons under curatorship who may be included in the study.

Treatment and study plan

Biological samples (blood and bone marrow samples).

Other

For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.

Primary outcomes

  1. Time to appearance of spectrum 2, defined as the delay between date of birth and appearance of an event classified as spectrum 2.

    Time frame: 5 years for each patient

    Spectrum 2 corresponds to MDS (Myelodysplastic Syndromes) with excess blasts, AML (Acute myeloid Leukemia) or CMML (Chronic myelomonocytic leukemia).

Secondary outcomes

  1. Time to appearance of spectrum 1, defined as the delay between date of birth and appearance of spectrum 1.

    Time frame: 5 years for each patient

    Spectrum 1 corresponds to hypoplastic marrow and/or low-grade MDS (without excess blasts).

  2. Time to appearance of first hematological event defined by the delay between date of birth and appearance of first hematological.

    Time frame: 5 years for each patient

  3. Disease Free Survival (DFS) defined as the time from Leukemia diagnosis until first /relapse or death from any cause.

    Time frame: 5 years for each patient

Study contacts

Contact information is provided by the study sponsor or research team.

Marlène PASQUET

CONTACT

[email protected]

+33 5 34 55 86 08

Sponsors and collaborators

Lead sponsor

Institut Claudius Regaud

Other

Registry information

Official study title

GATA-2 Project: Retrospective and Prospective Exploratory Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation

Acronym: GATA-2

Important dates

Study start
2023
Primary completion
2033
Study completion
2033
First posted
Aug 9, 2023
Registry last updated
Dec 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.